ADH4 (Alcohol Dehydrogenase 4 (Class II), Pi Polypeptide)

Single-cell RNA sequencing distribution analysis showed that ADH5 and ADH1B were significantly enriched in Fibroblasts cell clusters, and ADH7 was significantly enriched in Basal cells cell clusters. Our study provides key targets and pathways for understanding the complex molecular mechanisms by which FA affects lung cancer, reveals complex relationships that are difficult to find by traditional toxicological methods, and provides insights into strategies for preventing lung cancer caused by FA exposure.

Single-cell analysis identified six major cell types, providing a deeper understanding of the cellular heterogeneity within LIHC. In summarize, this study presents the first integrated apoptosis-cholesterol metabolic pathway-based six-gene prognostic model for LIHC, validated for robustness across multiple cohorts, which may facilitate personalized therapeutic strategies and refined risk assessment in clinical practice.

In summary, this study established a prognostic risk model for HCC based on GSH metabolism-related genes, which could predict the prognosis and characterize immune infiltration status of HCC. This study may contribute to the identification of potential prognostic targets and the development of new clinical management strategies for HCC.

By integrating transcriptomic and proteomic screening with epitope-level validation, we identified a novel panel of immunogenic biomarkers suitable for nanomaterial-enabled diagnostics in HCC. These findings support the translational potential of peptide-nano scaffold conjugates in developing minimally invasive, immune-responsive biosensing and therapeutic tools tailored for early-stage liver cancer management.

We have developed and validated an innovative prognostic risk model for GC, revealing that elevated ADMERGs risk scores are indicative of unfavorable prognosis and diminished immunotherapy response. These findings furnish molecular evidence regarding the participation of ADMERGs in modulating the immune microenvironment and therapeutic responsiveness in GC.

Single-cell analysis showed that G6PD and S100A9 were high-expressed mainly in hematopoietic progenitor cells (HPCs) and macrophages. In conclusion, this study screened four key genes based on PMRGs and constructed a risk model to effectively predict the prognosis of HCC, providing novel potential targets and theoretical basis for the molecular subtyping and individualized treatment of HCC.

In vivo experiments showed that SPP1 knockdown inhibited tumor growth and fatty acid metabolism of HCC mice. In conclusion, SPP1 is a pivotal gene that influences HCC prognosis by enhancing malignancy and drug resistance through fatty acid metabolism.

According to the results, POU3F3 acts as a protective regulator against sorafenib-induced ferroptosis in HCC cells by enhancing the transcription of multiple retinoic acid metabolism genes and promoting retinoic acid production. The POU3F3 inhibitor, rosarin, shows potential as an ideal candidate for overcoming sorafenib resistance in HCC.

The risk model constructed using lipid metabolism-related genes could effectively predict prognosis and was related to the immunosuppressive microenvironment and ICB immunotherapy. The hub genes related to the risk model were potential therapeutic targets.

The chemotherapeutic drug sensitivity analysis revealed significant differences in sensitivity to BI.2536 [a Polo-like kinase 1 (Plk1) inhibitor], A.443654 [a protein kinase B (Akt) 1/2 inhibitor], and ABT.888 [Veliparib, a poly(ADP-ribose) polymerase 1/2 (PARP1/2) inhibitor] between the high- and low-risk groups. It also elucidated the pathogenesis of MTDM-associated HCC. Our findings provide novel insights that could lead to the development of future therapeutic strategies.

The integrative analysis provides new insights into molecular complexities of BRCA. Immune profiles and gene signatures hold potential for improving stratification of BRCA patients and guiding the development of personalized immunotherapy strategies.

This seven-gene-based model showed stable outcomes in predicting HCC prognosis as well as responses to immunotherapy.